PRZOOM - /newswire/ -
Miami, FL, United States, 2011/09/02 - Henry Gazay, CEO of Medimix International and VoxMedTM, was named one of the 100 most influential people in the life sciences industry, selected by PharmaVoice readers for his vision in market research and passion for innovation.
Medimix International announced that Henry Gazay, CEO of Medimix International and VoxMedTM, has been named as one of the 100 most influential people in the life sciences industry. He was nominated and selected by PharmaVoice readers for his vision in the area of market research and his passion for innovation.
“The PharmaVOICE 100 are individuals in the life-sciences industry who are ”navigating the bumps and curves of today’s road to industry success, with fearless confidence and inventive maneuvering”…..”who think outside the box, pioneer new paths to success, and inspire their colleagues in the industry," said Taren Grom, editor-in-chief and cofounder of PharmaVOICE.
A serial entrepreneur and global marketing expert with 20-plus years’ experience, Henry has pioneered online market research in the pharma, biotech, and medical device sectors. He has developed new techniques, such as electronic patient charts, global on-line discussion forums, continuous trackers, and social media monitoring.
In February, 2011, after three years of intense development, he launched VoxMedTM, the first social media community for healthcare professionals around the world. VoxMedTM helps them connect with their peers in a secure and verified platform, engage each other on timely subjects, self-publish articles, share information, and engage with stakeholders in their industry.
“It is through years of perseverance, hard work and commitment to our clients that I owe this recognition,” commented Henry. “Through the dedication and leadership of every loyal member of Medimix, we have made our company a respected player in a very competitive field.”
A regular speaker at various conferences in Europe, US, Asia and Latin America, Henry is also a board member of Pharmaceutical Business Intelligence Research Group, and actively involved In EphMRA, PMRG, and ESOMAR.